FLEPGO 100 REPORT AT THE ANDROLOGY UNIT – 115 PEOPLE’S HOSPITAL

On September 18, 2025, at the Andrology Unit of People’s Hospital 115, Medbolide Pharma JSC successfully hosted the “Seminar Introducing FLEPGO 100 (Avanafil 100 mg)—A Solution for Erectile Dysfunction and Erectile Treatment—Onset Within 15 Minutes After Ingestion.”

Through the seminar, doctors had the opportunity to gain a deeper understanding of FLEPGO 100 and its effectiveness in treating erectile dysfunction. Erectile dysfunction is currently the most common sexual dysfunction among men. It affects not only the patient’s physical and mental health but also that of their partner and the couple’s overall happiness. FLEPGO 100, containing 100 mg of the active ingredient avanafil, is a new-generation PDE5 inhibitor that selectively and specifically inhibits PDE5 in penile erectile tissue, helping to:

• Fastest onset of erection—within 15 minutes after taking the medication
• Fewest side effects among PDE5 inhibitors
• Twice as effective in treating erectile dysfunction as sildenafil across all severity levels
• Effective in patients with dyslipidemia, diabetes, hypertension, etc., who have failed other erectile dysfunction treatments
• Shows good response in patients with severe erectile dysfunction and those who have undergone prostatectomy.

Following the seminar, the doctors spoke highly of the FLEPGO 100 product and expressed their hope for successful treatment of men with erectile dysfunction. At the same time, Medbolide extended its gratitude to the doctors and expressed its hope to continue partnering with the Andrology Unit at 115 People’s Hospital in providing effective treatment solutions and improving patients’ quality of life.